FIG. 7.

Inhibition of EMSA by competitors and antibodies. EMSA with the AP-1 (A) and AP-2 (B) probes. The nuclear extract from IPTG-treated U937/NS13 cells was incubated with 50- (50×) to 100-fold (100×) excess amounts of unlabeled AP-1 or AP-2 oligonucleotide or with 100-fold excess amounts of AP-1m or AP-2m, NF-κB, or Egr-1 oligonucleotide prior to binding with the FITC-labeled AP-1 or AP-2 probe. The nuclear extract was also incubated with antibodies against AP-1 or AP-2, NF-κB, Egr-1, or NS1 prior to the binding reaction. EMSA was performed as described in the legend to Fig. 6. The presence (+) or absence (−) of antibody, probe competitor, probe, and nuclear extract from U937/CAT12 cells (C) and U937/NS13 cells (N) is indicated above the gel. In both panels, lane 2 is a control and does not contain nuclear extract.